Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.

Yin S, Cheryan VT, Xu L, Rishi AK, Reddy KB.

PLoS One. 2017 Aug 17;12(8):e0183578. doi: 10.1371/journal.pone.0183578. eCollection 2017.

2.

Family matters: How MYC family oncogenes impact small cell lung cancer.

Brägelmann J, Böhm S, Guthrie MR, Mollaoglu G, Oliver TG, Sos ML.

Cell Cycle. 2017 Aug 18;16(16):1489-1498. doi: 10.1080/15384101.2017.1339849. Epub 2017 Jul 24.

PMID:
28737478
3.

MYC Modulation around the CDK2/p27/SKP2 Axis.

Hydbring P, Castell A, Larsson LG.

Genes (Basel). 2017 Jun 30;8(7). pii: E174. doi: 10.3390/genes8070174. Review.

4.

Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties.

Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M, Liu S, Jiang X, Zheng J, Zhang X, Chen P.

EBioMedicine. 2017 May;19:18-30. doi: 10.1016/j.ebiom.2017.04.014. Epub 2017 Apr 12.

5.

Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.

Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, Bogorad RL, Goel S, Yuzugullu H, Kauffman KJ, Yang J, Jin C, Li Y, Floris D, Swanson R, Ng K, Sicinska E, Anders L, Zhao JJ, Polyak K, Anderson DG, Li C, Sicinski P.

Cancer Cell. 2017 Apr 10;31(4):576-590.e8. doi: 10.1016/j.ccell.2017.03.004.

PMID:
28399412
6.

Mechanisms of the anti-tumor activity of Methyl 2-(-5-fluoro-2-hydroxyphenyl)-1 H-benzo[d]imidazole-5-carboxylate against breast cancer in vitro and in vivo.

Hasanpourghadi M, Pandurangan AK, Karthikeyan C, Trivedi P, Mustafa MR.

Oncotarget. 2017 Apr 25;8(17):28840-28853. doi: 10.18632/oncotarget.16263.

7.

RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.

Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, Ma W, Lim J, O'Brien S, Keats J, Yang J, Davis RE, Orlowski RZ.

Br J Haematol. 2017 Apr;177(1):80-94. doi: 10.1111/bjh.14525.

PMID:
28369725
8.

Modeling and Targeting MYC Genes in Childhood Brain Tumors.

Hutter S, Bolin S, Weishaupt H, Swartling FJ.

Genes (Basel). 2017 Mar 23;8(4). pii: E107. doi: 10.3390/genes8040107. Review.

9.

Strategies to Inhibit Myc and Their Clinical Applicability.

Whitfield JR, Beaulieu ME, Soucek L.

Front Cell Dev Biol. 2017 Feb 23;5:10. doi: 10.3389/fcell.2017.00010. eCollection 2017. Review.

10.

Cell cycle proteins as promising targets in cancer therapy.

Otto T, Sicinski P.

Nat Rev Cancer. 2017 Jan 27;17(2):93-115. doi: 10.1038/nrc.2016.138. Review.

11.

Oncogenic regulation of tumor metabolic reprogramming.

Tarrado-Castellarnau M, de Atauri P, Cascante M.

Oncotarget. 2016 Sep 20;7(38):62726-62753. doi: 10.18632/oncotarget.10911. Review.

12.

Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue.

Dasgupta A, Nomura M, Shuck R, Yustein J.

Int J Mol Sci. 2016 Dec 23;18(1). pii: E23. doi: 10.3390/ijms18010023. Review.

13.

MicroRNA-based screens for synthetic lethal interactions with c-Myc.

Li Y, Zhu Y, Prochownik EV.

RNA Dis. 2016;3(3). pii: e1330. Epub 2016 May 30.

14.

Elucidating the druggable interface of protein-protein interactions using fragment docking and coevolutionary analysis.

Bai F, Morcos F, Cheng RR, Jiang H, Onuchic JN.

Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8051-E8058. Epub 2016 Nov 29.

15.

Drugging the addict: non-oncogene addiction as a target for cancer therapy.

Nagel R, Semenova EA, Berns A.

EMBO Rep. 2016 Nov;17(11):1516-1531. Epub 2016 Oct 4. Review.

16.

Synthetic lethality in lung cancer and translation to clinical therapies.

Leung AW, de Silva T, Bally MB, Lockwood WW.

Mol Cancer. 2016 Sep 29;15(1):61. Review.

17.

Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.

Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, Freemantle SJ, Dmitrovsky E.

Mol Cancer Ther. 2016 Nov;15(11):2758-2766. Epub 2016 Aug 22.

18.

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, Workman P, Chesler L.

Oncotarget. 2016 Sep 6;7(36):57525-57544. doi: 10.18632/oncotarget.10544.

19.

DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.

Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G, Kim JW, Ehrenberger T, Clemons PA, Dančík V, Seashore-Ludlow B, Viswanathan V, Stewart ML, Rees MG, Shamji A, Schreiber S, Fraenkel E, Pomeroy SL, Mesirov JP, Tamayo P, Eberhart CG, Raabe EH.

Clin Cancer Res. 2016 Aug 1;22(15):3903-14. doi: 10.1158/1078-0432.CCR-15-3011. Epub 2016 Mar 24.

20.

microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.

Han H, Chen Y, Cheng L, Prochownik EV, Li Y.

Oncotarget. 2016 Mar 29;7(13):16409-19. doi: 10.18632/oncotarget.7653.

Supplemental Content

Support Center